Editorials
How Can We Improve the Use of Established Therapies in PsA?  P. Nash  ................................................................. 1153

APOL1 Gene — Implications for Systemic Lupus Erythematosus  L.T. Hiraki  ................................................................. 1155

Mixed Crystal Disease: A Tale of 2 Crystals  E. Pascual, F. Sivera, M. Andres ................................................................. 1158

Rheumatoid Arthritis
Cervical Spine Involvement among Patients with RA Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study  T. Sandström, V. Rantalaaho, T. Yi-Kerttula, et al, for the NEO-RACo Study Group ................................................................. 1160

Reliability of MRI Scoring of the Metatarsophalangeal Joints of the Foot according to the RA MRI Score  Y.J. Dakkak, X.M. Matthijssen, D. van der Heijde, M. Reijnierse, A.H. van der Helm-van Mil ................................................................. 1165

Reasons for Biologic and Targeted Synthetic DMARD Cessation and Persistence of Second-line Treatment in an RA Dataset  P. Youssef, B. Marcal, P. Button, et al ................................................................. 1174

Spondyloarthritis
Reliability and Validity of Patient-reported Outcomes Measurement Information System Short Forms in AS  M.C. Hwang, A. Ogdie, A. Puravath, J.D. Revelle ....................................................................................... 1182

Long-term Effect on Leisure Time Physical Activity Level in Individuals with AxSpA: Secondary Analysis of a Randomized Controlled Trial  S.H. Sveaas, H. Dagfinrud, M.W. Johansen, E. Pedersen, O.M. Wold, A. Bilberg ................................................................. 1189

Psoriatic Arthritis

Association of Pharmacological Biomarkers with Treatment Response and Long-term Disability in Patients with PsA: Results from OUTPASS  M. Jani, H. Chinoy, A. Barton, for OUTPASS ....................................................................................... 1204

Systemic Lupus Erythematosus

Systemic Sclerosis
How SSc Affects Healthcare Use and Complication Rates after Total Hip Arthroplasty  J.A. Singh, J.D. Cleveland ....................................................................................... 1218

Vasculitis
Characteristics of Takayasu Arteritis Patients with Severe Ischemic Events  R.Y. Yu, R. AlSolimani, N. Khalidi, C. Pagnoux, L. Barra, for the Canadian Vasculitis Network ....................................................................................... 1224

Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study  C. Heijl, K. Westman, P. Höglund, A.J. Mohammad ................................................................. 1229

Pediatric Rheumatology
The Effect of Morning Stiffness Duration on the Definition of Clinically Inactive Disease in JIA  M. Allegra, M.F. Gicchino, G. Giancane, et al ....................................................................................... 1238

Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma  S.C. Li, K.S. Torok, C.E. Rabinovich, et al, for the CARRA Registry Investigators ....................................................................................... 1242

Osteoarthritis
Use of Recommended Non-surgical Knee OA Management in Patients prior to Total Knee Arthroplasty: A Cross-sectional Study  L.K. King, D.A. Marshall, P. Faris, et al, for the BEST-Knee Team ....................................................................................... 1253

Contents continued on page xii
Gout
Acute Calcium Pyrophosphate Crystal Arthritis Flare Rate and Risk Factors for Recurrence

Other Arthritides
Chronic Joint Pain 3 Years after Chikungunya Virus Infection Largely Characterized by Relapsing-remitting Symptoms
Economic Analysis of the Use of Anti-DFS70 Antibody Test in Patients with Undifferentiated Systemic Autoimmune Disease Symptoms
L. Moroni, G. Restovic, R. Cervera, et al. ................. 1275
Opioid Use among Patients with Early Inflammatory Arthritides Compared to the General Population
P. Muilu, V. Rantalaiho, H. Kautiainen, L.J. Virta,
K. Puolakka .................................................. 1285

Images in Rheumatology
Severe Acute Atelectasis Caused by Complete Obstruction of Left Main Stem Bronchus Associated with Granulomatosis with Polyangiitis
R. Kuwata, Y. Shirata, T. Ishii ................................. 1293

Letters
Understanding the Biological Significance of Anti-DFS70 Antibodies: Effect of Biologic Therapies on Their Occurrence in Inflammatory Arthritis
T. Carbone, C. Esposito, V. Patundi, et al. ................. 1295
Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases:
A Descriptive Observational Analysis
E.G. Favalli, E. Agape, R. Caporalli ......................... 1296
Case Report of Refractory PsA Achieving Remission Using Nigella sativa (Black Seed Oil) Extract
M.A. Rida, D.D. Gladman .................................... 1297
Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database
C. Mettler, L. Chouchana, B. Terrier ....................... 1298

Meetings ....................................................... iv